Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset
February 9, 2018 8:52 AM ESTGoldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $25.00) while maintaining a Buy rating following the company's 4Q earnings and meetings with management.
While 2018 guidance came in lower than expected, analyst Jami Rubin believes it helps reset investor expectations and,... More
Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo
February 9, 2018 8:05 AM ESTWells Fargo lowered its price target on Teva Pharma (NYSE: TEVA) to $16.50 (from $17.00) while maintaining an Underperform rating.
"We believe the conference call went poorly and reinforced worries about the weak 2018 guidance," analyst David Maris commented.
Lowers FY 2018 EPS to $2.43, which compares to Tevas guidance of $2.25-2.50.
... MoreTeva Pharma (TEVA) PT Lowered to $16 at Cowen
February 8, 2018 12:37 PM ESTCowen lowered its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Ken Cacciatore commented, "We have updated our model. The bottom-line is with the free cash flow expected to reach $2.6-2.8B this doesn't... More
Teva Pharma (TEVA) Leaving Room for Upside Surprise in EBITDA Guidance - Evercore ISI
February 8, 2018 8:32 AM ESTEvercore ISI analyt Umer Raffat said Teva Pharma (NYSE: TEVA) EBITDA expectations at $4.7-$5B (vs sell side at $5.3B) leaves a "healthy room in there for surprising to the upside either on more realized cost cuts or on lesser Copaxone erosion."
"Said another... More
